Olmetec Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmetec Plus, is an Angiotensin II receptor blocker presented as an oral tablet for systemic use. It is combined with hydrochlorothiazide, a thiazide diuretic, to treat hypertension in adult patients.

GNH USA supplies Olmetec Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmetec Plus, an ARB‑thiazide combination, is indicated for the management of high blood pressure. - Hypertension (essential): lowers systolic and diastolic pressure, reducing cardiovascular risk. - Hypertension requiring diuretic therapy: adds fluid‑removing effect to improve blood pressure control. - Hypertension with fluid retention: provides combined vasodilation and diuresis for better therapeutic outcome.

Common Side Effects: - Dizziness or light‑headedness - Headache - Increased urination or thirst - Fatigue - Mild electrolyte disturbances (e.g., low potassium) - Dry mouth

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury or worsening renal function - Hyperkalemia or severe electrolyte imbalance - Allergic reactions such as rash or angioedema - Pancreatitis - Blood dyscrasias (e.g., agranulocytosis)

Olmetec Plus should be used with caution in several clinical situations. - Renal function: monitor serum creatinine and potassium regularly. - Electrolyte balance: check sodium and potassium levels, especially in patients on other diuretics. - Pregnancy: avoid unless benefits outweigh potential risks. - Concomitant NSAIDs: may diminish antihypertensive effect and affect renal function. - Volume depletion: use cautiously in patients with hypovolemia or on high‑dose diuretics. - Store at ambient temperature: keep in original container, protect from moisture and light.

Olmetec Plus may interact with several medicines, requiring attention to avoid adverse outcomes. Major Interactions (Avoid): - Aliskiren in patients with diabetes: increased risk of renal impairment. - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - Lithium: heightened lithium toxicity. Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive response. - ACE inhibitors or other ARBs: additive effect on potassium levels. - Cyclosporine or tacrolimus: may raise serum creatinine.